News Merck sets sights on Epstein-Barr virus jab with Opko deal Licensing agreement includes $50m upfront, with a total value of $922.5m, including milestones.
News Redx slumps after it abandons trial of lead cancer drug Study of porcupine inhibitor RXC004 in combination with Merck's Keytruda will continue.
News Merck’s cardiovascular pipeline delivers at ACC Data on sotatercept in PAH and oral PCSK9 MK-0616 boost Merck's hopes for the franchise.
News Merck drops last phase 3 Keytruda trial in prostate cancer KEYNOTE-641 showed no benefit when added to Xtandi for castration-resistant prostate cancer.
News Merck will appeal EU rejection of COVID drug Lagevrio CHMP says evidence for the drug is “not adequate” to show efficacy over standard care.
News Keytruda shadows GSK's Jemperli in endometrial cancer GSK had just two months to celebrate the positive phase 3 result with its checkpoint inhibitor Jemperli as a first-line therapy for endometrial cancer, before Merck &
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
